Evaluation of drug-drug interaction between Suraxavir Marboxil (GP681) and itraconazole, and assessment of the impact of gene polymorphism

Evaluation of drug-drug interaction between Suraxavir Marboxil (GP681) and itraconazole, and assessment of the impact of gene polymorphism

IntroductionSuraxavir Marboxil (GP681) is a prodrug metabolized to GP1707D07, which inhibits influenza viral replication by targeting cap-dependent endonuclease through a single oral dose. This study assesses the in vivo drug-drug interaction (DDI) potential between GP681 (including its major metabo...

Full description

Saved in:
Bibliographic Details
Main Authors: Mai Han, Gang Cui, Yan Zhao, Xianbo Zuo, Xiaoxue Wang, Xin Zhang, Na Mi, Jiangli Jin, Chunyan Xiao, Jing Wang, Wei Wu, Yajuan Li, Jintong Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Pharmacology
Subjects:
DDI (drug-drug interaction)
itraconazole
Suraxavir Marboxil (GP681)
safety
genetic polymorfism
pharmacokinetic
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1505557/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1505557/full

Similar Items